欧康维视生物(01477.HK)拟折让4.9%配股 净筹7.8亿元
欧康维视生物(01477.HK)公布,拟以先旧後新配售2,800万股股份,占扩大後股本4.52%,每股配售价28.35元,较昨日收市价折让4.87%。
公司预计,配售所得款项净额约为7.83亿元,将用作扩大公司的商业团队,鉴於公司计划推出新疗法,包括OT-401(YUTIQ)(核心产品)及OT-601(莫西沙星);为公司疗法的国际多中心临床试验提供资金,包括但不限於OT1001(Zerviate)、OT-301(NCX-470)、OT-702(Eylea生物类似药)、OT-101(低浓度阿托品)及OT-202(TKI);建设和发展苏州夏翔生物医药的新生产设施和设备以及原料药(API)生产设施以及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.